Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HCV viral load~* HCV genotype~* HCV qualitative~* HCV antibody~* HCV drug~* Continuously enrolled 12 months~Exclusion Criteria:~* Each outcome will be analyzed separately as time to first event, thus people who experience an outcome prior to their study start date are ineligible for analyses related to that particular outcome.~The results will be examined for sensitivity to the following possible exclusion criteria:~* Achieved SVR-12 prior to index date~* HCV treatment experienced prior to index date~* No visit in GI, Infectious Disease, or Liver Transplant / Hepatology~* No positive HCV test (genotype, viral load, or qualitative)~* No recent positive HCV test (genotype, viral load or qualitative)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 88 Years
- Healthy Volunteers: None

Study Arms:
- Direct Acting Antivirals (Type: None): Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.
- Comparison (Type: None): The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication)

Based on this trial design, predict the completion outcome and termination type (if applicable).